ArticleClinicoEconomics and outcomes research : CEOR2025

Consequences of Canada's Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access.

Nigel S B RawsonPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.